Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

AIB1 is a predictive factor for tamoxifen response in premenopausal women.

Alkner, Sara LU ; Bendahl, Pär-Ola LU ; Grabau, Dorthe LU ; Lövgren, Kristina LU ; Stål, O ; Rydén, Lisa LU orcid and Fernö, Mårten LU (2010) In Annals of Oncology 21. p.238-244
Abstract
BACKGROUND: Clinical trials implicate the estrogen receptor (ER) coactivator amplified in breast cancer 1 (AIB1) to be a prognostic and a treatment-predictive factor, although results are not unanimous. We have further investigated this using a controlled randomised trial of tamoxifen versus control. Materials and methods: A total of 564 premenopausal women were entered into a randomised study independent of ER status. Using a tissue microarray, AIB1 and ER were analysed by immunohistochemistry. RESULTS: AIB1 scores were obtained from 349 women. High AIB1 correlated to factors of worse prognosis (human epidermal growth factor receptor 2, Nottingham histological grade 3, and lymph node metastases) and to ER negativity. In the control arm,... (More)
BACKGROUND: Clinical trials implicate the estrogen receptor (ER) coactivator amplified in breast cancer 1 (AIB1) to be a prognostic and a treatment-predictive factor, although results are not unanimous. We have further investigated this using a controlled randomised trial of tamoxifen versus control. Materials and methods: A total of 564 premenopausal women were entered into a randomised study independent of ER status. Using a tissue microarray, AIB1 and ER were analysed by immunohistochemistry. RESULTS: AIB1 scores were obtained from 349 women. High AIB1 correlated to factors of worse prognosis (human epidermal growth factor receptor 2, Nottingham histological grade 3, and lymph node metastases) and to ER negativity. In the control arm, high AIB1 was a negative prognostic factor for recurrence-free survival (RFS) (P = 0.02). However, ER-positive patients with high AIB1 responded significantly to tamoxifen treatment (P = 0.002), increasing RFS to the same level as for systemically untreated patients with low AIB1. Although ER-positive patients with low AIB1 had a better RFS from the beginning, this was not further improved by tamoxifen (P = 0.8). CONCLUSIONS: In the control group, high AIB1 was a negative prognostic factor. However, ER-positive patients with high AIB1 responded significantly to tamoxifen. This implicates high AIB1 to be an independent predictive factor of improved response to tamoxifen and not, as has previously been discussed, a factor predicting tamoxifen resistance. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of Oncology
volume
21
pages
238 - 244
publisher
Oxford University Press
external identifiers
  • wos:000274087600009
  • pmid:19628566
  • scopus:77949519750
  • pmid:19628566
ISSN
1569-8041
DOI
10.1093/annonc/mdp293
language
English
LU publication?
yes
id
fdbb60fe-6d58-4be6-b72e-b7051851342f (old id 1452852)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19628566?dopt=Abstract
date added to LUP
2016-04-04 09:44:32
date last changed
2025-04-04 15:22:58
@article{fdbb60fe-6d58-4be6-b72e-b7051851342f,
  abstract     = {{BACKGROUND: Clinical trials implicate the estrogen receptor (ER) coactivator amplified in breast cancer 1 (AIB1) to be a prognostic and a treatment-predictive factor, although results are not unanimous. We have further investigated this using a controlled randomised trial of tamoxifen versus control. Materials and methods: A total of 564 premenopausal women were entered into a randomised study independent of ER status. Using a tissue microarray, AIB1 and ER were analysed by immunohistochemistry. RESULTS: AIB1 scores were obtained from 349 women. High AIB1 correlated to factors of worse prognosis (human epidermal growth factor receptor 2, Nottingham histological grade 3, and lymph node metastases) and to ER negativity. In the control arm, high AIB1 was a negative prognostic factor for recurrence-free survival (RFS) (P = 0.02). However, ER-positive patients with high AIB1 responded significantly to tamoxifen treatment (P = 0.002), increasing RFS to the same level as for systemically untreated patients with low AIB1. Although ER-positive patients with low AIB1 had a better RFS from the beginning, this was not further improved by tamoxifen (P = 0.8). CONCLUSIONS: In the control group, high AIB1 was a negative prognostic factor. However, ER-positive patients with high AIB1 responded significantly to tamoxifen. This implicates high AIB1 to be an independent predictive factor of improved response to tamoxifen and not, as has previously been discussed, a factor predicting tamoxifen resistance.}},
  author       = {{Alkner, Sara and Bendahl, Pär-Ola and Grabau, Dorthe and Lövgren, Kristina and Stål, O and Rydén, Lisa and Fernö, Mårten}},
  issn         = {{1569-8041}},
  language     = {{eng}},
  pages        = {{238--244}},
  publisher    = {{Oxford University Press}},
  series       = {{Annals of Oncology}},
  title        = {{AIB1 is a predictive factor for tamoxifen response in premenopausal women.}},
  url          = {{http://dx.doi.org/10.1093/annonc/mdp293}},
  doi          = {{10.1093/annonc/mdp293}},
  volume       = {{21}},
  year         = {{2010}},
}